{"nct_id":"NCT01207388","title":"Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","status_verified_date":"2020-01","start_date":"2010-11","start_date_type":null,"primary_completion_date":"2014-02","primary_completion_date_type":"ACTUAL","completion_date":"2019-01-07","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["AMGN"]}